U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874530) titled 'Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+' on Dec. 03, 2024.
Brief Summary: This is a non-interventional, national, multicentre retrospective and prospective observational study aiming at assessing the efficacy of isatuximab-based regimens in RRMM patients with 1q21+ in a real-life setting.
Due to the limited information as to isatuximab's impact in real-world settings and that MM is a rare cancer, patients will be enrolled both prospectively and retrospectively from approximately 8 haematologic/oncologic centers in Italy. Prospective enrollment will allow an assessment of true baseli...